Inventor · disambiguated record
Hua Xu
Also filed as: XU HUA · Xu hua-dong
6 granted patents·14 pending applications·92 citations·filing 1993–2023
82Inventor score
Files withFOCHON BIOSCIENCES LTD3UNIV CALIFORNIA3FOCHON PHARMACEUTICALS LTD2TELIK INC2ACAD OF MILITARY MEDICAL SCIENCES1
Top patents by PatentIndex Score
20 records- 0190US6355433B1Determination of nucleotide sequence variations through limited primer extensionDNA SCIENCES INC·Filed 2000·Granted Mar 12, 2002·38 cites·45 claims
- 0272US5504000AChimeric protein tyrosine kinasesUNIV CALIFORNIA·Filed 1995·Granted Apr 2, 1996·22 cites·5 claims
- 0370US5439819AChimeric protein tyrosine kinasesUNIV CALIFORNIA·Filed 1993·Granted Aug 8, 1995·20 cites·7 claims
- 0464US2008159980A1Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapyTELIK INC·Filed 2007·Application pending·0 cites
- 0562US5670324AUse of chimeric CD4-src protein tyrosine kinases in drug screening and detection of an immune responseUNIV CALIFORNIA·Filed 1995·Granted Sep 23, 1997·12 cites·10 claims
- 0662US2023382946A1Polypeptide or protein directional modification method based on sulfhydryl-alkenyl azide couplingUNIV CHANGZHOU·Filed 2023·Application pending·0 cites
- 0761US2025101490A1Method for screening acetylcholinesterase inhibitorACAD OF MILITARY MEDICAL SCIENCES·Filed 2023·Application pending·0 cites
- 0857US2004138140A1Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapyTELIK INC·Filed 2003·Application pending·0 cites
- 0953US2022356521A1Methods for detecting, monitoring, and guiding treatment of allograft rejection using discriminating gene expression signaturesCAREDX INC·Filed 2022·Application pending·0 cites
- 1052US2007282537A1Rapid characterization of post-translationally modified proteins from tandem mass spectraUNIV OHIO STATE·Filed 2007·Application pending·0 cites
- 1152US2025122191A1Compounds as bcl-2 inhibitorsFOCHON BIOSCIENCES LTD·Filed 2022·Application pending·0 cites
- 1251US2023159527A1Compounds as bcl-2 inhibitorsFOCHON PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 1350US2024174637A1Degraders of grk2 and uses thereofPIIZZI GRAZIA·Filed 2022·Application pending·0 cites
- 1449US2022354860A1Heterocyclic derivatives and use thereofFOCHON PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 1548US2023174556A1Compounds as protein kinase inhibitorsFOCHON BIOSCIENCES LTD·Filed 2021·Application pending·0 cites
- 1647US2023135215A1Compounds as cdk2/4/6 inhibitorsFOCHON BIOSCIENCES LTD·Filed 2021·Application pending·0 cites
- 1746US2023009608A1Grk2 inhibitors and uses thereofCYGNAL THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1844US2013123117A1Capture probe and assay for analysis of fragmented nucleic acidsUNIV LELAND STANFORD JUNIOR·Filed 2012·Application pending·0 cites
- 1931US8410163B2Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitorsBEROZA PAUL P·Filed 2010·Granted Apr 2, 2013·0 cites·13 claims
- 2030US5981248AMammalian cell death preventing kinase, DPKAMGEN INC·Filed 1997·Granted Nov 9, 1999·0 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when Hua Xu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →